ClinicalTrials.gg
CompletedNCT03662100Updated Jan 25, 2024Results posted

A Study of Two Formulations of LY3074828 in Healthy Participants

A Phase 1 interventional study of LY3074828 and LY3074828 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-25.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828 when given as different formulations. The tolerability of LY3074828 will also be evaluated and information about any side effects experienced will be collected.

Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 12 weeks, not including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Healthy participants.

Exclusion Criteria:

  • Must not have an average weekly alcohol intake that exceeds 21 units/week (males) and 14 units/week (females)
  • Must not show evidence of active or latent tuberculosis (TB)
  • Must not have received (s) (including attenuated live vaccines and those administered intranasally) within 8 weeks of screening, or intend to during the study
  • Must not have been treated with within 1 month of screening, or intend to during the study
  • Must not be
  • Must not have received treatment with biologic agents (e.g. monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to Day 1
  • Must not have significant allergies to humanised monoclonal antibodies
  • Must not have multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe post treatment reactions
  • Must not have had lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years
  • Must not have had breast cancer within the past 10 years
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Test 1: 250 mg LY3074828

    Participants received 250 mg LY3074828 solution formulation (1 x 2-mL 125-milligram/milliliter \[mg/mL\]) administered subcutaneously (SC) via an auto-injector (AI) in arm.

    Biological: LY3074828 · Device: Auto-injector (AI)

  • Experimental
    Test 2: 250 mg LY3074828

    Participants received 250 mg LY3074828 solution formulation (1 x 2-mL 125-mg/mL) administered SC via an AI in thigh.

    Biological: LY3074828 · Device: Auto-injector (AI)

  • Experimental
    Test 3: 250 mg LY3074828

    Participants received 250 mg LY3074828 solution formulation (1 x 2-mL 125-mg/mL) administered SC via an AI in abdomen.

    Biological: LY3074828 · Device: Auto-injector (AI)

  • Experimental
    Reference 1: 250 mg LY3074828

    Participants received 250 mg LY3074828 solution formulation (2 x 1-mL 125-mg/mL) in pre-filled syringe (PFS) administered as subcutaneous (SC) injection in arm. The second injection was administered 20 (±2) minutes after the first injection.

    Drug: LY3074828 · Device: Prefilled syringe (PFS)

  • Experimental
    Reference 2: 250 mg LY3074828

    Participants received 250 mg LY3074828 solution formulation (2 x 1-mL 125-mg/mL) in PFS administered as SC injection in thigh. The second injection was administered 20 (±2) minutes after the first injection.

    Drug: LY3074828 · Device: Prefilled syringe (PFS)

  • Experimental
    Reference 3: 250 mg LY3074828

    Participants received 250 mg LY3074828 solution formulation (2 x 1-mL 125-mg/mL) in PFS administered as SC injection in abdomen. The second injection was administered 20 (±2) minutes after the first injection.

    Drug: LY3074828 · Device: Prefilled syringe (PFS)

Interventions

  • BiologicalLY3074828

    Administered SC

  • Administered SC

  • DeviceAuto-injector (AI)

    AI to administer LY3074828

  • DevicePrefilled syringe (PFS)

    PFS to administer LY3074828

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Maximum Concentration (Cmax) of LY3074828 by Device

    Pharmacokinetics: Cmax of LY3074828

    Time frame: Day 1: 0, 2, 6 hours (hr), Day 2: 24 hr, Day 4, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, Day 85, Post dose

  2. Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC(0-∞)) of LY3074828 by Device

    Pharmacokinetics: Area Under the Concentration versus Time Curve From Time Zero to Infinity (AUC(0-∞)) of LY3074828

    Time frame: Day 1: 0, 2, 6 hours (hr), Day 2: 24 hr, Day 4, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, Day 85, Post dose

  3. Visual Analogue Scale (VAS) Pain Assessment by Device

    The VAS is a single-item participant-rated assessment of injection pain. Score is reported on a continuous scale of 0 to 100. Higher values indicate more pain.

    Time frame: Day 1: 1, 5 (±1.5) and 15 (±2) minutes

  4. Visual Analogue Scale (VAS) Pain Assessment by Device and Injection Site Location

    The VAS is a single-item participant-rated assessment of injection pain. Score is reported on a continuous scale of 0 to 100. Higher values indicate more pain.

    Time frame: Day 1: 1, 5 (±1.5) and 15 (±2) minutes

07

Results

Posted Jan 25, 2024

Participant flow

Participant flow — Overall Study
MilestoneTest 1: 250 mg LY3074828Test 2: 250 mg LY3074828Test 3: 250 mg LY3074828Reference 1: 250 mg LY3074828Reference 2: 250 mg LY3074828Reference 3: 250 mg LY3074828
Started111111111111
Received at least one dose of drug111111111111
Completed111111111111
Not completed000000

Outcome measures

PrimaryPharmacokinetics: Maximum Concentration (Cmax) of LY3074828 by Device

Pharmacokinetics: Cmax of LY3074828

Time frame:
Day 1: 0, 2, 6 hours (hr), Day 2: 24 hr, Day 4, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, Day 85, Post dose
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Pharmacokinetics: Maximum Concentration (Cmax) of LY3074828 by Device
micrograms per milliliter (μg/mL)250 mg LY3074828 AI250 mg LY3074828 PFS
Pharmacokinetics: Maximum Concentration (Cmax) of LY3074828 by Device22.2 ± 4018.7 ± 34
PrimaryPharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC(0-∞)) of LY3074828 by Device

Pharmacokinetics: Area Under the Concentration versus Time Curve From Time Zero to Infinity (AUC(0-∞)) of LY3074828

Time frame:
Day 1: 0, 2, 6 hours (hr), Day 2: 24 hr, Day 4, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, Day 85, Post dose
Reported as:
Geometric mean · microgram*day per millileter (μg*day/mL)
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC(0-∞)) of LY3074828 by Device
microgram*day per millileter (μg*day/mL)250 mg LY3074828 AI250 mg LY3074828 PFS
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC(0-∞)) of LY3074828 by Device357 ± 38340 ± 38
PrimaryVisual Analogue Scale (VAS) Pain Assessment by Device

The VAS is a single-item participant-rated assessment of injection pain. Score is reported on a continuous scale of 0 to 100. Higher values indicate more pain.

Time frame:
Day 1: 1, 5 (±1.5) and 15 (±2) minutes
Reported as:
Mean · millimeter
Visual Analogue Scale (VAS) Pain Assessment by Device
millimeter250 mg LY3074828 AI First Injection250 mg LY3074828 PFS First Injection250 mg LY3074828 PFS Second Injection
1 min25.2 ± 20.022.6 ± 18.318.3 ± 15.1
5 min (±1.5)12.0 ± 15.86.1 ± 7.06.0 ± 6.7
15 min (±2)1.9 ± 3.12.4 ± 2.82.2 ± 4.3
PrimaryVisual Analogue Scale (VAS) Pain Assessment by Device and Injection Site Location

The VAS is a single-item participant-rated assessment of injection pain. Score is reported on a continuous scale of 0 to 100. Higher values indicate more pain.

Time frame:
Day 1: 1, 5 (±1.5) and 15 (±2) minutes
Reported as:
Mean · millimeter
Visual Analogue Scale (VAS) Pain Assessment by Device and Injection Site Location
millimeter250 mg LY3074828 AI First Injection250 mg LY3074828 PFS First Injection250 mg LY3074828 PFS Second Injection
Arm: 1 min25.9 ± 17.219.0 ± 12.015.6 ± 12.3
Arm: 5 min (±1.5)5.6 ± 5.44.5 ± 5.55.0 ± 6.0
Arm: 15 min (±2)2.6 ± 4.81.8 ± 2.42.0 ± 2.9
Thigh: 1 min26.8 ± 15.519.6 ± 20.920.5 ± 19.6
Thigh: 5 min (±1.5)13.1 ± 12.36.2 ± 6.67.9 ± 7.8
Thigh:15 min (±2)0.9 ± 1.33.0 ± 3.63.5 ± 6.7
Abdomen: 1 min22.9 ± 27.229.2 ± 20.618.7 ± 13.4
Abdomen: 5 min (±1.5)17.4 ± 23.37.5 ± 8.85.0 ± 6.4
Abdomen: 15 min (±2)2.2 ± 2.12.4 ± 2.41.2 ± 1.9

Adverse events

Collected over Up To 85 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test 1: 250 mg LY30748280/11 (0%)0/11 (0%)3/11 (27.3%)
Test 2: 250 mg LY30748280/11 (0%)0/11 (0%)6/11 (54.5%)
Test 3: 250 mg LY30748280/11 (0%)0/11 (0%)2/11 (18.2%)
Reference 1: 250 mg LY30748280/11 (0%)0/11 (0%)3/11 (27.3%)
Reference 2: 250 mg LY30748280/11 (0%)0/11 (0%)6/11 (54.5%)
Reference 3: 250 mg LY30748280/11 (0%)0/11 (0%)4/11 (36.4%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventTest 1: 250 mg LY3074828Test 2: 250 mg LY3074828Test 3: 250 mg LY3074828Reference 1: 250 mg LY3074828Reference 2: 250 mg LY3074828Reference 3: 250 mg LY3074828
TachycardiaCardiac disorders0/110/110/110/111/110/11
Refraction disorderEye disorders0/110/111/110/110/110/11
NauseaGastrointestinal disorders0/110/110/110/111/110/11
Influenza like illnessGeneral disorders1/111/110/111/110/110/11
Injection site bruisingGeneral disorders0/111/111/111/110/111/11
NasopharyngitisInfections and infestations0/110/110/110/111/110/11
ContusionInjury, poisoning and procedural complications0/111/110/110/110/110/11
Corneal abrasionInjury, poisoning and procedural complications0/110/110/110/110/111/11
LacerationInjury, poisoning and procedural complications1/110/110/110/110/110/11
Limb injuryInjury, poisoning and procedural complications0/110/110/110/111/110/11

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Test 1: 250 mg LY3074828Test 2: 250 mg LY3074828Test 3: 250 mg LY3074828Reference 1: 250 mg LY3074828Reference 2: 250 mg LY3074828Reference 3: 250 mg LY3074828Total
Mean44.6 ± 14.339.9 ± 13.745.4 ± 9.444.1 ± 14.742.8 ± 12.345.0 ± 12.943.6 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Test 1: 250 mg LY3074828Test 2: 250 mg LY3074828Test 3: 250 mg LY3074828Reference 1: 250 mg LY3074828Reference 2: 250 mg LY3074828Reference 3: 250 mg LY3074828Total
Female76667739
Male45554427
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Test 1: 250 mg LY3074828Test 2: 250 mg LY3074828Test 3: 250 mg LY3074828Reference 1: 250 mg LY3074828Reference 2: 250 mg LY3074828Reference 3: 250 mg LY3074828Total
Hispanic or Latino44544728
Not Hispanic or Latino77677438
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Test 1: 250 mg LY3074828Test 2: 250 mg LY3074828Test 3: 250 mg LY3074828Reference 1: 250 mg LY3074828Reference 2: 250 mg LY3074828Reference 3: 250 mg LY3074828Total
American Indian or Alaska Native0000000
Asian2000002
Native Hawaiian or Other Pacific Islander0000000
Black or African American14414014
White8661071148
More than one race0110002
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(Participants)Test 1: 250 mg LY3074828Test 2: 250 mg LY3074828Test 3: 250 mg LY3074828Reference 1: 250 mg LY3074828Reference 2: 250 mg LY3074828Reference 3: 250 mg LY3074828Total
United States11111111111166
08

Study locations

1 site
  • Covance Clinical Research Inc
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Jan 2019, 4 months.

Results were first posted in Jan 2024, 5 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2018
First posted
Sep 7, 2018
StartActual
Sep 6, 2018
Primary completionActual
Jan 25, 2019
CompletionActual
Jan 25, 2019
Results first posted
Jan 25, 2024
Last update
Jan 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03662100
Responsible party
Sponsor
First posted
Sep 7, 2018
Start date
Sep 6, 2018
Primary completion
Jan 25, 2019
Completion
Jan 25, 2019
Results posted
Jan 25, 2024
Last update
Jan 25, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion